Table 1:

Reports of sinus bradycardia in patients with COVID-19 receiving remdesivir

Study	Age, yr; sex	Bradycardia onset relative to remdesivir initiation	Risk factors for bradycardia	Lowest heart rate, BPM	Other ECG abnormalities	Clinical sequelae	Time to recovery after drug discontinuation
Gupta et al.8	26; F	Day 2, nadir on day 3	None	40	Prolonged QT/QTc to 628/555 ms^* (from 388/439 ms) with T-wave abnormalities	Asymptomatic	Within 48–72 h
Gupta et al.8	77; F	Day 3	Age	48	None	Asymptomatic	Within 48 h
Sanchez-Codez et al.5	13; M	Day 3	None	40	None	Asymptomatic	Within 24 h
Gubitosa et al.7	54; F	Day 2, nadir on day 4	None	34	QRS widening to 170 ms (from 168 ms before administration and 150 ms baseline) and QTc prolongation to 496 ms (from 440–460 ms)^†	Angina and hypotension requiring atropine	Within 4 d^†
Current case	59; M	Day 3	None	50	None	Asymptomatic	Within 72 h

Note: BPM = beats per minute, ECG = electrocardiogram.
↵* On azithromycin until the day before discontinuation of remdesivir.
↵† From correspondence with Gubitosa et al., Feb. 2021 (Dr. James Gubitosa [Department of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey]: personal communication, 2021).